Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1874 • ACR Convergence 2020
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Mark Hwang¹, Martin Rozycki², Theresa Arndt², Esther Yi³ and Michael Weisman⁴, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Healthcare claims databases can be used to identify patients with ankylosing spondylitis (AS) prior to diagnosis. This study explores differences in pathways to AS…
Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
Abstract Number: 0341 • ACR Convergence 2020
Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity
Wei Han¹, Xiaohang Wang¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: In this work, we applied a high-performance chemical isotope labeling (CIL) LC-MS platform to search for biomarker candidates of PsA and AS in human…
Abstract Number: 0892 • ACR Convergence 2020
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
Sergio Schwartzman¹, David Sandoval², Andris Kronbergs², Jeffrey Lisse³, Himanshu Patel³, Wen Xu³, Soyi Liu-Leage³, Marina Magrey⁴, Helena Marzo-Ortega⁵ and Denis Poddubnyy⁶, ¹Weill Cornell Medical College, New York, NY, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum (ankylosing spondylitis and…
Abstract Number: 1323 • ACR Convergence 2020
Pregnancy in Axial Spondyloarthropathy: A Systematic Review & Meta-Analysis
Sinead Maguire¹, Tom O'Dwyer², Fiona Wilson³, David Mockler³ and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²Independent Researcher, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis affecting the sacroiliac joints and the spine. Although this chronic condition affects a wide range of ages,…
Abstract Number: 1517 • ACR Convergence 2020
Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived Indoles in Ankylosing Spondylitis
Adam Berlinberg¹, Adam Lefferts², Emilie Regner³, Andrew Stahly⁴ and Kristine Kuhn⁴, ¹University of Colorado, Denver, CO, ²University of Colorado, Anschutz Medical Campus, Denver, CO, ³University of California San Francisco, San Francisco, CA, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Intestinal microbial dysbiosis, intestinal inflammation, and Th17 immunity are all linked to the pathophysiology of ankylosing spondylitis (AS); however, the mechanisms linking them remain…
Abstract Number: 1875 • ACR Convergence 2020
Heterogeneity Amongst Men and Women with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Zhixiu Li¹, Muhammad Khan², Mohammad Khan³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Sjef van der Linden⁷ and Matthew Brown⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Case Western Reserve University, Cleveland OH, Westlake, OH, ³Kent State University, Kent, OH, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁸Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial disease (nr-axSpA). Our purpose was to investigate genetic heterogeneity of clinically diagnosed axSpA.Methods:…
Abstract Number: 1904 • ACR Convergence 2020
Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis
Xenofon Baraliakos¹, Rebecca Bolce², David Sandoval², Soyi Liu-Leage³, Vladimir Geneus³, David Adams³, Atul Deodhar⁴, Jessica Walsh⁵ and Joachim Sieper⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Oregon Health & Science University, Portland, OR, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
Abstract Number: 555 • 2019 ACR/ARP Annual Meeting
Oncostatin M Receptor (OSMR) Underexpression in Patients with Ankylosing Spondylitis
Maria Andreza Correia ¹, Claudia Marques¹, Anderson Almeida ¹, Vitor Silva ¹, Nara Cavalcanti ¹, Moacyr Rego ¹, Angela Duarte ¹ and Maira Pitta ², ¹Universidade Federal de Pernambuco, Recife, Brazil, ²Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
Background/Purpose: Oncostatin M receptor (OSMR), that binding to oncostatin M (OSM) cytokine are associated with inflammation and cell's growth and differentiation. OSM uses the OSMR to…
Abstract Number: 615 • 2019 ACR/ARP Annual Meeting
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Paras Karmacharya¹, Ravi Shahukhal ², Cynthia Crowson ³, M.Hassan Murad ⁴, Pragya shrestha ⁵, Delamo Bekele ⁶, Kerry Wright ⁴, John Davis ⁴ and Maureen Dubreuil ⁷, ¹Reading Hospital, Mayo Clinic, Rochester, ²Lakes Regional General Hospital, Laconia, NH, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic. Rochester, MN, Rochester, MN, ⁶Mayo Clinic Rochester, Rochester, MN, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: Most studies show a significantly higher risk of myocardial infarction [MI] (odds ratio [OR] = 1.60) and stroke (OR = 1.50) in ankylosing spondylitis (AS)…
Abstract Number: 1480 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Meghan Glynn ³, Blessing Dube ², Robert McLean ³, Esther Yi ⁴, Yujin Park ⁵ and Philip Mease ⁶, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Secukinumab is the only non–tumor necrosis factor inhibitor biologic therapy approved for the treatment of ankylosing spondylitis (AS) in the United States. Patients with…
Abstract Number: 1913 • 2019 ACR/ARP Annual Meeting
Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis
Benjamin Naovarat¹, Michael Weisman ², Lianne Gensler ³, Michael Ward ⁴, Mark Hwang ¹, Amirali Tahanan ¹, MinJae Lee ¹, Mohammad Rahbar ¹, Mariko Ishimori ⁵, Matthew Brown ⁶ and John Reveille ⁷, ¹University of Texas-McGovern Medical School, Houston, TX, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University San Francisco California, San Francisco, CA, ⁴NIAMS, Bethesda, MD, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Queensland University of Technology, Queensland, Australia, ⁷University of Texas McGovern Medical School, Houston
Background/Purpose: Recent studies have suggested that peripheral arthritis in patients with spondyloarthritis is associated with HLA-B*15. Studies of white patients with psoriatic arthritis (PsA) have…
Abstract Number: 564 • 2019 ACR/ARP Annual Meeting
ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis
Jae-Bum Jun¹, Bon San Koo ², Seunghun Lee ³, Jinju Kim ⁴, Juyeon Kang ¹ and Tae-Hwan Kim ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ³Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Novartis Korea Ltd., Seoul
Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF…
Abstract Number: 617 • 2019 ACR/ARP Annual Meeting
Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp ¹, Mikhail Protopopov², Fabian Proft ³, Joachim Sieper ³, Hildrun Haibel ³, Martin Rudwaleit ⁴ and Denis Poddubnyy ⁵, ¹Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁴Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Peripheral involvement (PI), such as arthritis, enthesitis, and dactylitis, is common in patients with axial spondyloarthritis (axSpA); data showing the influence of PI on…
Abstract Number: 1482 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Georg Schett¹, Xenofon Baraliakos ², Filip Van den Bosch ³, Atul Deodhar ⁴, Lianne Gensler ⁵, Mikkel Østergaard ⁶, Shital Agawane ⁷, Ayan Das Gupta ⁷, Shephard Mpofu ⁸, Todd Fox ⁸, Adam Winseck ⁹, Brian Porter ⁹ and Abhijit Shete ⁸, ¹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Ghent University Hospital, Ghent, Belgium, ⁴Oregon Health & Science University, Portland, OR, ⁵University San Francisco California, San Francisco, CA, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].